Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
612.00    -13.00 (-2.08%)
Bid:
610.00
Ask:
612.00
Spread: 2.00 (0.328%)
Market Cap: £740.58m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Holding(s) in Company

6 Jul 2017 07:15

RNS Number : 2518K
Oxford Biomedica PLC
06 July 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oxford Biomedica plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 187,227,017*

 

HSBC Global Custody Nominee (UK) Limited 42,906,072*

State Street Nominees Limited 8,432,060*

 

*denotes direct interest

 

Chase (GA Group) Nominees Limited 10,620,273

 

Chase Nominees Limited 5,994,501

 

Vidacos Nominees Limited 11,910,298

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

04/07/2017

6. Date on which issuer notified (DD/MM/YYYY):

05/07/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.646%

0.265%

8.911%

3,088,726,215

Position of previous notification (if

applicable)

9.213%

0. 265%

9.478%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB0006648157

238,565,149

28,525,072

7.723%

0.923%

SUBTOTAL 8. A

267,090,221

8.646%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

8,198,196*

 

DIRECT INTEREST

0.265%

SUBTOTAL 8. B 1

8,198,196

0.265%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

8.646%

8.911%

Aviva Group Holdings Limited

8.646%

8.911%

Aviva Investors Holdings Limited

8.646%

8.911%

Aviva Investors Global Services Limited

8.646%

8.911%

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

This notification is prompted by a 8% to 7% change at Direct Interest Level (Box 8A&B)

 

Place of completion

Norwich, England

Date of completion

5 July 2017

Contact name:

Tim Watts

Contact telephone number:

01865 783000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUVSNRBNABRAR
Date   Source Headline
2nd Jun 20267:00 amRNSOXB Capital Markets Event
1st Jun 20267:00 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirector Declaration
22nd May 20262:17 pmRNSDirector/PDMR Shareholding
19th May 20269:56 amRNSPDMR Dealing
13th May 202610:52 amRNSPDMR Dealing
7th May 20264:58 pmRNSResult of AGM
1st May 20267:00 amRNSTotal Voting Rights
30th Apr 20268:15 amRNSAdmission to Trading
27th Apr 20269:51 amRNSAdmission to Trading Application
13th Apr 20267:00 amRNS-RLaunch of viral vector fast-track offering
8th Apr 20265:18 pmRNSGrant of Awards
1st Apr 20267:00 amRNSTotal Voting Rights
30th Mar 20263:30 pmRNS2026 Annual General Meeting notification
26th Mar 20267:00 amRNSPreliminary results for the year ended 31 Dec 2025
18th Mar 20267:00 amRNS-RLicensing agreement with VVMF
9th Mar 20267:53 amRNSAdmission to Trading
4th Mar 202611:45 amRNSAdmission to Trading Application
3rd Mar 20267:00 amRNSCapital Markets Day and investor conferences
2nd Mar 20267:00 amRNSTotal Voting Rights
27th Feb 20261:31 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
26th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
26th Feb 20261:49 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
26th Feb 202612:33 pmRNSForm 8.3 - Oxford Biomedica plc
26th Feb 202611:09 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
26th Feb 202611:08 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
26th Feb 20269:42 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica plc
25th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
25th Feb 20262:32 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
25th Feb 202612:33 pmRNSResponse to Rule 2.8 Announcement
25th Feb 202612:12 pmRNSDisclosure Table
25th Feb 202612:00 pmRNSRule 2.8 Announcement
25th Feb 202611:46 amRNSForm 8.3 - Oxford Biomedica plc
25th Feb 202610:53 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica Plc
25th Feb 202610:17 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
25th Feb 202610:15 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
24th Feb 20267:29 amRNSForm 8.5 (EPT/RI)-Oxford Biomedica plc
24th Feb 20267:25 amRNSForm 8.5 (EPT/NON-RI)-Oxford Biomedica plc
24th Feb 20267:03 amRNSFull year Trading Update and Notice of Results
23rd Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
23rd Feb 20262:20 pmEQSForm 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
23rd Feb 20267:40 amRNSForm 8.5 (EPT/RI)-Oxford Biomedica plc
23rd Feb 20267:39 amRNSForm 8.5 (EPT/NON-RI)-Oxford Biomedica plc
20th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
20th Feb 20261:46 pmRNSForm 8.3 - Oxford Biomedica Plc
20th Feb 20268:13 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
20th Feb 20268:08 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
19th Feb 20262:39 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
19th Feb 20269:44 amRNSRule 2.9 Announcement
19th Feb 20268:04 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.